Related Experiment Video

Updated: May 6, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.4K

Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and

Yong-Liang Yao1, Jie Shao, Chunfu Zhang

  • 1Department of Clinical Laboratory, Kunshan First People's Hospital, Affiliated to Jiangsu University, Kunshan, Jiangsu, China.

Plos One
|November 9, 2013
PubMed

Insights

Receptor tyrosine kinase (RTK) overexpression, not just mutations, drives colorectal cancer (CRC) cell survival. Targeting specific RTKs like ErbB2 and c-Met offers personalized CRC treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Activating mutations in receptor tyrosine kinase (RTK) pathways are key in many cancers, including colorectal cancer (CRC).
  • The role of RTK overexpression as an alternative driver of CRC pathogenesis remains less understood.
  • Distinct RTKs may activate different downstream signaling pathways in various CRC subtypes.

Purpose of the Study:

  • To investigate if RTK overexpression, independent of mutations, contributes to CRC.
  • To determine if specific RTKs (ErbB2, ErbB3, c-Met) are overexpressed in CRC.
  • To explore the downstream signaling pathways (AKT, MAPK) activated by RTK overexpression and their role in CRC cell survival.

Main Methods:

  • Immunohistochemistry was used to assess the expression levels of ErbB2, ErbB3, and c-Met in colorectal cancer patient samples.
  • Specific RTK inhibitors (Lapatinib for ErbB2, PHA-665752 for c-Met) were employed to evaluate the necessity of constitutive RTK activation for cancer cell survival.
  • Downstream signaling pathway activation (AKT and MAPK) was analyzed in relation to RTK overexpression patterns.

Main Results:

  • Differential overexpression of ErbB2, ErbB3, and c-Met was observed in colorectal cancer patient samples, leading to constitutive activation of RTK signaling.
  • Inhibition of ErbB2 and c-Met demonstrated that constitutive RTK signaling is essential for colorectal cancer cell survival.
  • The pattern of RTK overexpression correlated with the activation of distinct downstream AKT and/or MAPK pathways.

Conclusions:

  • RTK overexpression is a significant factor in colorectal cancer pathogenesis, complementing mutation-driven models.
  • Targeting specific overexpressed RTKs is crucial for colorectal cancer cell survival.
  • RTK expression profiles can predict downstream pathway activation, informing personalized therapeutic strategies for CRC patients.

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

10.4K
In vitro Organoid Culture of Primary Mouse Colon Tumors07:33

In vitro Organoid Culture of Primary Mouse Colon Tumors

Published on: May 17, 2013

34.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K